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Sestre milosrdnice University Hospital, Zagreb, Croatia
SUMMARY ∑ Although melanoma is less common than other types of malignant skin tumors, in-
cluding basal and squamous cell cancers, it accounts for about 75% of all skin cancer deaths. Mela-
noma is much more likely to metastasize to other parts of the body, which is not the case with other
types of skin tumors. Metastatic spread is very common, particularly in advanced tumors of higher
Clark and Breslow stage. The aim of the study was to analyze the prevalence and distribution of
metastatic melanomas among biopsy specimens collected during the 1995-2000 period, and their
relationship with primary melanoma, especially regarding Clark and Breslow staging. Metastatic mela-
nomas were found in 210 of 75,390 (0.3%) surgical biopsies. There were 24 patients with 57 meta-
static melanoma biopsies related to primary melanoma diagnosed at our hospital during the period
of observation. The remaining 153 metastatic melanomas diagnosed at other hospitals or before the
period of observation were not included in the study. Metastatic melanomas were more common in
male patients (13 male and 11 female), age range 16-91 (mean age 53.0) years. In men, age range was
16-75, and in women 23-91 years. Metastatic melanomas occurred 1 month to 2 years (mean 4.9
months) after the diagnosis. They affected patients with Clark III-V and Breslow III-V. Metastases
were not observed in Clark I-II patients, however, two metastases were detected in patients with
Breslow thickness II. Also, a statistically significant increase in the prevalence of metastatic and pri-
mary melanomas (p<0.01 both) was recorded during the period of observation.
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Introduction
The incidence of melanoma has risen at least 20-fold
in the past century1. The rise in melanoma incidence has
been observed in whites, particularly in Scandinavia,
Australia, North America, Scotland, and Germany. In the
United States and Germany, approximately 38,000 and
10,000 new cases, respectively, are diagnosed per year2.
However, according to the last report of the National
Registry of Cancer, the incidence of melanoma in Croatia
decreased from 6.5/100,000 in 1995 to 5.3/100,000 in
19983. As a result of increased public awareness, melano-
mas are more commonly diagnosed in earlier stages and
most are surgically cured. However, some patients still
present with advanced tumors. Metastatic spread to re-
gional lymph nodes and distant sites is very common,
particularly in tumors thicker than 2 mm4-7. Metastasis
usually occurs within few years from the diagnosis. The
most important attributes that may help predict the me-
tastasis and prognosis of melanoma are Breslow’s thick-
ness and Clark’s level of invasion4-8. Other major prog-
nostic factors are ulceration, anatomic location, and
patient’s sex5,9.
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The aim of the study was to analyze the prevalence and
distribution of metastatic melanoma among biopsy speci-
mens in the 1995-2000 period, and their relationship with
primary melanoma.
Patients and Methods
Computed surgical pathology registry at the Depart-
ment of Pathology was canvassed for the 1995-2000 pe-
riod to identify all patients with primary and metastatic
melanomas. All relevant data including age and sex of the
patients, histologic type, presence of ulceration, level of
invasion, and tumor thickness were analyzed. The depth
of invasion and tumor thickness were determined accord-
ing to Clark and Breslow, respectively10,11. The patients
with metastatic melanoma diagnosed in the period of
observation were divided into two subgroups according to
the level of invasion and tumor thickness: those with Clark
I-II and Breslow I-II primary tumor, and those with Clark
III-IV and Breslow III-V primary tumor. Primary ocular
melanomas were excluded from the investigation.
Statistical analysis was performed by Statistica soft-
ware on an IBM PC/AT compatible computer. The ob-
served frequencies were tested by χ2-test.
Results
During the above mentioned period, there were
75,390 surgical biopsies, and 347 (0.46%) were skin mela-
noma related biopsies. Primary skin melanoma was found
in 137 (0.18%) biopsies. Analyzing the prevalence of skin
melanoma, we found 13 primary melanomas in 1995 ver-
sus 37 in 2000 (Fig. 1). Primary melanomas were more
common in females (78 cases in females and 59 in males),
with a female to male ratio of 1.3:1 (Fig. 2). In the pe-
riod of observation, the mean age of patients with primary
melanoma was 59.0 years, however, younger and older
patients were recorded towards the end of the period, es-
pecially among women. A majority of primary tumors
were diagnosed at an advanced stage (Clark III-V, Breslow
III-V). The distribution of primary melanomas accord-
ing to Clark and Breslow staging is shown in Table 1.
Another 210 (0.3%) biopsies were metastatic melano-
mas related either to primary melanomas diagnosed in the
period from January 1, 1995 till December 31, 2000 (24
patients with 57 biopsies), and at another hospital or be-
Table 1. Distribution of primary melanomas during the 1995 ∑










Fig. 1. Total number of biopsies at the Department of Pathology
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1995 1996 1997 1998 1999 2000 Total
female 9 10 9 15 15 20 78
male 4 12 7 5 14 17 59
female
male
Fig. 2. Prevalence and sex distribution of primary melanoma in
biopsy material during the 1995-2000 period
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fore the observed period (153 biopsies) (Fig. 3). In this
study, the group of 24 patients with primary melanoma
who had presented during the 1995-2000 period were
further analyzed.
Among 66 patients with primary melanomas who we-
re regularly followed at the Department of Oncology of
the Sestre milosrdnice University Hospital from Zagreb,
metastases were observed in 24 (36.4%) patients (13 male
and 11 female), age range 16-91 (mean age 53.0) years.
Metastatic melanoma occurred between 1 month and 2
years (mean 4.9 months) from the diagnosis. There was
a statistically significant difference in the prevalence of
primary (χ2=16.96, d.f.=5, p<0.01) and metastatic
(χ2=33.36, d.f.=5, p<0.01) melanomas in the examined
period. Among 24 patients with primary melanoma, there
were 12 nodular melanomas, 7 superficially spreading
melanomas, and two cases with acral type of melanoma.
In three patients, the histologic type could not have been
determined. Ulceration was present in 9 of 24 melanomas
(6 nodular, 2 superficially spreading, and one acral mela-
noma). Metastatic melanoma was found in 20 patients
with Clark III-V. In four patients, Clark level was not
determined because the tumor extended to the specimen
margin. Concerning Breslow’s thickness, metastases oc-
curred in two patients with Breslow I-II and 19 patients
with Breslow III-V. In three patients, Breslow thickness
could not be determined because the tumor was not com-
pletely excised. Skin was most commonly involved by me-
tastases (n=18), followed by lymph nodes in 14 and other
sites in 25 cases. Numerous metastases were observed in
one patient with acral melanoma, three patients with
melanoma of the nasal cavity, and one patient with mela-
noma of the anal region.
Discussion
Major factors associated with the incidence of mela-
noma include race and ethnicity, sunlight exposure, and
genetic and familial predisposition9. Major factors asso-
ciated with melanoma prognosis include tumor thickness,
ulceration, anatomic localization, and patient’s sex5,9,12,13.
Other less important factors are mitotic count, cellular
polymorphism, vascular invasion, and regression. Evalu-
ation of large databases showed that tumor thickness was
the most important prognostic variable studied5. In our
study, metastases were significantly more common in pa-
tients with Clark and Breslow stages III-V. We found
metastatic melanoma to predominantly affect the skin and
regional lymph nodes, as also reported by others2,14-16.
This could in part be due to sentinel lymph node biop-
sies that have relatively recently been introduced in clini-
cal practice, as also noted elsewhere5,8,14-16. In a study
reported by Jansen et al.15, sentinel lymph nodes were
identified in 27 out of 30 patients with melanoma of the
head and neck region. The sentinel node was positive in
eight patients15. In a study by Averbook et al.16 including
133 patients who underwent lymph node dissection, 28
(21.1%) patients had nodal metastases. Patients with a
primary melanoma thicker than 4 mm had 50% metastatic
involvement of their lymph nodes16. It is obvious that sen-
tinel lymph node biopsy will increase the number of iden-
tified positive lymph nodes. However, as summarized by
Balch17, sentinel lymph node lymphadenectomy has mul-
tiple advantages in the care of melanoma patients with
clinically normal nodes, who may have occult metastases.
Several studies have demonstrated that the sentinel lymph
node evaluation for the underlying metastatic disease re-
flects the status of the entire lymph node region, and is
therefore a useful prognostic factor2,14,15,17. A multi-insti-
tutional study has stressed the sentinel lymph node sta-
tus as the most significant prognostic factor superior to the
measurement of tumor thickness in primary melano-
ma2,14,15,17.
The peak hazard rate for death from metastatic mela-
noma was recorded in the 48 months of follow-up2. Af-
ter 120-month survival, the risk of dying from metastatic
melanoma is very low, approaching zero2. In our study,
metastases occurred 1 month to 2 years from the diagno-
sis. Vollmer reviewed 11 large studies and observed ulcer-
ation to be an additional significant prognostic factor in

















1995 1996 1997 1998 1999 2000 Total
female 11 14 11 16 38 33 123
male 5 16 17 13 13 23 87
female
male
Fig. 3. Prevalence and sex distribution of metastatic melanoma in
biopsy material during the 1995-2000 period
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frequently diagnosed in patients with large, ulcerated tu-
mors. Primary tumors were more common in females,
while metastatic melanomas were more common in males.
It has been suggested that women with metastatic mela-
noma have better prognosis than males19, however, we
could not confirm this observation. In up to 4% of patients
presenting initially with metastatic melanoma, no primary
tumor can be found20. In our series, primary melanoma
was identified in all 24 cases.
There was a statistically significant increase in meta-
static and primary melanomas diagnosed at our Hospital
in the 1995-2000 period. However, official data from the
National Cancer Registry showed a decreasing incidence
during the 1995-1998 period3. This discordance could
probably be due to the larger number of patients treated
at our Hospital, or to some failure in the registration of
melanoma patients. It seems that this topic should be fur-
ther evaluated.
We also observed an increasing number of primary
melanoma in younger and older patients with a small gap
in middle ages. There was a wider range in the pathohi-
stologic stages among primary melanomas, however, the
reason for this phenomenon is uncertain. Should it be
attributed to better diagnosis, or it simply reflected a re-
cent increase in the number of melanoma patients, or
both?
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Saæetak
METASTATSKI MELANOM U BIOPSIJSKOM MATERIJALU U RAZDOBLJU OD 1995. DO 2000. GODINE
B. Kruπlin, D. Müller, I. Nola, M. VuËiÊ, I. Novosel, A. JakovËeviÊ, J. BroziÊ, D. DeSyo, H. »upiÊ i M. Belicza
Melanom je rjei od ostalih vrsta malignih tumora koæe, ukljuËuje bazocelularni i planocelularni rak, ali uzrokuje oko 75%
svih smrti od raka koæe. Melanom ima veÊu vjerojatnost metastaziranja u druge dijelove tijela, πto nije sluËaj s drugim vrstama
koænih tumora. Metastatsko πirenje je vrlo Ëesto, poglavito kod uznapredovalih tumora viπega stadija po Clarku i Breslowu.
Cilj ovoga ispitivanja bio je analizirati uËestalost i raspodjelu metastatskih melanoma meu biopsijskim uzorcima u razdoblju
od 1995. do 2000. godine, te njihov odnos s primarnim melanomom, poglavito u smislu Clarkove i Breslowljeve klasifikacije
prema stadijima bolesti. Metastatski melanomi naeni su u 210 od 75.390 (0,3%) kirurπkih biopsija. U razdoblju od 1995. do
2000. godine u naπoj su Bolnici dijagnosticirana 24 bolesnika s 57 biopsija metastatskih melanoma povezanih s primarnim
melanomom. Preostala 153 metastatska melanoma koji su dijagnosticirani u drugim bolnicama ili prije razdoblja promatranja
nisu ukljuËeni u ovo ispitivanje. Metastatski melanomi bili su ËeπÊi u muπkih negoli u æenskih bolesnika (13 muπkih i 11
æenskih) u dobi od 16 do 91 godine (srednja dob 53,0 godine). U muπkih se bolesnika dobni raspon kretao od 16 do 75 godina,
a u æenskih od 23 do 91 godine. Metastatski melanomi su se pojavili 1 mjesec do 2 godine nakon dijagnoze (srednja vrijednost
4,9 mjeseci). Metastatski melanom zahvatio je bolesnike sa stadijem III. ∑ V. prema Clarku te III. ∑ V. prema Breslowu.
Metastaze nisu zabiljeæene u bolesnika sa stadijem I. ∑ II. prema Clarku, meutim, dvije su metastaze nastale u bolesnika s
debljinom II. stupnja prema Breslowu. U ispitivanom razdoblju opaæen je i statistiËki znaËajan porast uËestalosti metastatskih
i primarnih melanoma (p<0,01 oboje).
KljuËne rijeËi: Melanom, dijagnostika; Melanom, patologija
